Comparative analysis of the therapeutic effects of long-acting and short-acting loop diuretics in the treatment of chronic heart failure using 123I-metaiodobenzylguanidine scintigraphy

European Journal of Heart Failure

Volumn 13, Issue 8, 2011, Pages 892-898

  Hisatake, Shinji ^a   Nanjo, Shuji ^a   Fujimoto, Shinichiro ^a   Yamashina, Shohei ^a   Yuzawa, Hitomi ^a   Namiki, Atsushi ^a   Nakano, Hajime ^a   Yamazaki, Junichi ^a  

^a TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

Author keywords

123I MIBG scintigraphy; Azosemide; Chronic heart failure; Diuretic; Furosemide

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; AZOSEMIDE; BRAIN NATRIURETIC PEPTIDE; DIURETIC AGENT; FUROSEMIDE; NORADRENALIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MALE; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCINTIGRAPHY; SYMPATHETIC NERVE; TREATMENT OUTCOME;

3-IODOBENZYLGUANIDINE; ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; CROSS-OVER STUDIES; FEMALE; FUROSEMIDE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; SULFANILAMIDES;

EID: 79961052072     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfr054     Document Type: Article

References (23)

1. Bonfils PK, Damgaard M, Taskiran M, Goetze JP, Norsk P, Gadsbøll N. Impact of diuretic treatment and sodium intake on plasma volume in patients with compensated systolic heart failure. Eur J Heart Fail 2010;12:995-1001.
2. MacFadyen RJ, Ng Kam Chuen MJ, Davis RC. Loop diuretic therapy in left ventricular systolic dysfunction: has familiarity bred contempt for a critical but potentially nephrotoxic cardio renal therapy? Eur J Heart Fail 2010;12:649-652.
3. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985;103:1-6. (Pubitemid 15068490)
4. Tsutsui T, Tsutamoto T, Maeda K, Kinoshita M. Comparison of neurohumoral effects of short-acting and long-acting loop diuretics in patients with chronic congestive heart failure. J Cardiovasc Pharmacol 2001;38(Supple 1):S81-85. (Pubitemid 33104689)
5. Yoshida J, Yamamoto K, Mano T, Sakata Y, Nishio M, Ohtani T, Hori M, Miwa T, Masuyama T. Different effects of long-and short-acting loop diuretics on survival rate in Dahl high-salt heart failure model rats. Cardiovasc Res 2005;68:118-127. (Pubitemid 41253562)
6. Patel AD, Iskandrian AE. MIBG imaging. J Nucl Cardiol 2002;9:75-94. (Pubitemid 34196234)
7. Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergic neuron-blocking agents; adrenomedullary imaging with [131I] iodobenzylguanidine. J Nucl Med 1980;21:349-353. (Pubitemid 10100562)
8. Henderson EB, Kahn JK, Corbett JR, Jansen DE, Pippin JJ, Kulkarni P, Ugolini V, Akers MS, Hansen C, Buja LM, Parkey RW, Willerson JT. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 1988;78:1192-1199.
9. Fukuoka S, Hayashida K, Hirose Y, Shimotsu Y, Ishida Y, Kakuchi H, Eto T. Use of iodine-123 metaiodobenzylguanidine myocardial imaging to predict the effectiveness of beta-blocker therapy in patients with dilated cardiomyopathy. Eur J Nucl Med 1997;24:523-529. (Pubitemid 27239211)
10. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, Ohnishi M, Sugimoto Y, Kinoshita M. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509-516. (Pubitemid 27329427)
11. Krück F, Bablok W, Besenfelder E, Betzien G, Kaufmann B. Clinical and pharmacological investigations of the new saluretic azosemide. Eur J Clin Pharmacol 1978;14:153-161. (Pubitemid 9069278)
12. Tomiyama H, Nakayama T, Watanabe G, Shiojima K, Sakuma Y, Yamamoto A, Imai Y, Yoshida H, Doba N. Effects of short-acting and long-acting loop diuretics on heart rate variability in patients with chronic compensated congestive heart failure. Am Heart J 1999;137:543-548. (Pubitemid 29124125)
13. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-367.
14. McCurley JM, Hanlon SU, Wei SK, Wedam EF, Michalski M, Haigney MC. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 2004;44:1301-1307. (Pubitemid 39208889)
15. Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999;100:1311-1315. (Pubitemid 29440124)
16. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717. (Pubitemid 29407370)
17. Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000;35:1025-1030. (Pubitemid 30327250)
18. Domanski M, Tian X, Haigney M, Pitt B. Diuretic use, progressive heart failure, and death in patients in the DIG study. J Card Fail 2006;12:327-332. (Pubitemid 43817590)
19. Fujimoto S, Inoue A, Hisatake S, Yamashina S, Yamashina H, Nakano H, Yamazaki J. Usefulness of 123I-metaiodobenzylguanidine myocardial scintigraphy for predicting the effectiveness of beta-blockers in patients with dilated cardiomyopathy from the standpoint of long-term prognosis. Eur J Nucl Med Mol Imaging 2004;31:1356-1361. (Pubitemid 39361930)
20. Imamura Y, Fukuyama T. Prognostic value of myocardial MIBG scintigraphy findings in patients with cardiomyopathy-importance of background correction for quantification of MIBG activity. Ann Nucl Med 2002;16:387-393. (Pubitemid 35407627)
21. Yamazaki J, Muto H, Kabano T, Yamashina S, Nanjo S, Inoue A. Evaluation of betablocker therapy in patients with dilated cardiomyopathy-Clinical meaning of iodine 123-metaiodo benzylguanidine myocardial single-photon emission computed tomography. Am Heart J 2001;141:645-652. (Pubitemid 32260734)
22. Kasama S, Toyama T, Sumino H, Matsumoto N, Sato Y, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure. J Nucl Med 2007;48:1993-2000. (Pubitemid 350232308)
23. Glowniak JV, Kilty JE, Amara SG, Hoffman BJ, Turner FE. Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters. J Nucl Med 1993;34:1140-1146. (Pubitemid 23191332)